Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · January 17, 2022

3-Year Safety Outcomes of AADC Gene Therapy for Moderately Advanced Parkinson Disease



Additional Info

Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial
Neurology 2022 Jan 04;98(1)e40-e50, CW Christine, RM Richardson, AD Van Laar, ME Thompson, EM Fine, OS Khwaja, C Li, GS Liang, A Meier, EW Roberts, ML Pfau, JR Rodman, KS Bankiewicz, PS Larson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading